Vincenzo Patella, Roberta Zunno, Girolamo Pelaia, Luciana Pierro, Giovanni Florio, Carmine Nicoletta, Corrado Pelaia
{"title":"生物制剂减轻药物负担,改善严重嗜酸性哮喘患者的身心健康。","authors":"Vincenzo Patella, Roberta Zunno, Girolamo Pelaia, Luciana Pierro, Giovanni Florio, Carmine Nicoletta, Corrado Pelaia","doi":"10.1080/02770903.2025.2490106","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This real-world study evaluates the improvement in asthma control, drug burden reduction, and physical and mental health in patients with severe eosinophilic asthma treated with biologicals.</p><p><strong>Methods: </strong>We enrolled 127 patients with severe eosinophilic asthma from two centers, treating them with add-on biological therapy. The asthma control test (ACT) and the Short-form Health Survey-12 (SF-12), including Physical Component Summary (PCS) and Mental Component Summary (MCS), were used, assessing drug history at baseline (T0) and after 32 weeks of biological therapy (T1).</p><p><strong>Results: </strong>A significant improvement in asthma control was observed after the biological treatment (ACT score: 11(8) vs 23(3), <i>p</i> < 0.0001), with most patients achieving asthma control at T1 (110, 86.6%). There was a statistically significant reduction in the use of non-biological drugs at T1, such as oral corticosteroids (40.2% vs 17.3%, <i>p</i> < 0.0001), inhalation therapy (75.6% vs 57.5%, <i>p</i> = 0.001), leukotriene receptor antagonists (34.6% vs 25.2%, <i>p</i> < 0.0001), and antihistamines (42.5% vs 18.1%, <i>p</i> < 0.0001). ACT and PCS scores at T1 had a strong positive correlation (<i>r</i> = 0.749, <i>p</i> < 0.0001), as did ACT and MCS scores (<i>r</i> = 0.744, <i>p</i> < 0.0001). Our study shows that the biological treatments for severe eosinophilic asthma, properly characterized through a careful phenotypic assessment, significantly improve asthma control and reduce drug burden (notably oral corticosteroids, inhalation therapy, leukotriene receptor antagonists, and antihistamines), as well as enhance both physical and mental health irrespective of age and sex.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1493-1498"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biologicals reduce drug burden and improve physical and mental health in severe eosinophilic asthma.\",\"authors\":\"Vincenzo Patella, Roberta Zunno, Girolamo Pelaia, Luciana Pierro, Giovanni Florio, Carmine Nicoletta, Corrado Pelaia\",\"doi\":\"10.1080/02770903.2025.2490106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This real-world study evaluates the improvement in asthma control, drug burden reduction, and physical and mental health in patients with severe eosinophilic asthma treated with biologicals.</p><p><strong>Methods: </strong>We enrolled 127 patients with severe eosinophilic asthma from two centers, treating them with add-on biological therapy. The asthma control test (ACT) and the Short-form Health Survey-12 (SF-12), including Physical Component Summary (PCS) and Mental Component Summary (MCS), were used, assessing drug history at baseline (T0) and after 32 weeks of biological therapy (T1).</p><p><strong>Results: </strong>A significant improvement in asthma control was observed after the biological treatment (ACT score: 11(8) vs 23(3), <i>p</i> < 0.0001), with most patients achieving asthma control at T1 (110, 86.6%). There was a statistically significant reduction in the use of non-biological drugs at T1, such as oral corticosteroids (40.2% vs 17.3%, <i>p</i> < 0.0001), inhalation therapy (75.6% vs 57.5%, <i>p</i> = 0.001), leukotriene receptor antagonists (34.6% vs 25.2%, <i>p</i> < 0.0001), and antihistamines (42.5% vs 18.1%, <i>p</i> < 0.0001). ACT and PCS scores at T1 had a strong positive correlation (<i>r</i> = 0.749, <i>p</i> < 0.0001), as did ACT and MCS scores (<i>r</i> = 0.744, <i>p</i> < 0.0001). Our study shows that the biological treatments for severe eosinophilic asthma, properly characterized through a careful phenotypic assessment, significantly improve asthma control and reduce drug burden (notably oral corticosteroids, inhalation therapy, leukotriene receptor antagonists, and antihistamines), as well as enhance both physical and mental health irrespective of age and sex.</p>\",\"PeriodicalId\":15076,\"journal\":{\"name\":\"Journal of Asthma\",\"volume\":\" \",\"pages\":\"1493-1498\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02770903.2025.2490106\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2490106","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究评估生物制剂对重度嗜酸性粒细胞性哮喘患者哮喘控制、药物负担减轻和身心健康的改善。方法:我们从两个中心招募了127例严重嗜酸性粒细胞性哮喘患者,对他们进行附加生物治疗。采用哮喘控制试验(ACT)和简易健康调查-12 (SF-12),包括生理成分总结(PCS)和心理成分总结(MCS),评估基线(T0)和生物治疗32周(T1)时的用药史。结果:经生物治疗(ACT评分:11(8)vs 23(3), p p p = 0.001),白三烯受体拮抗剂治疗(34.6% vs 25.2%, p pr = 0.749, pr = 0.744, p p 0.001)后,哮喘控制有显著改善
Biologicals reduce drug burden and improve physical and mental health in severe eosinophilic asthma.
Objective: This real-world study evaluates the improvement in asthma control, drug burden reduction, and physical and mental health in patients with severe eosinophilic asthma treated with biologicals.
Methods: We enrolled 127 patients with severe eosinophilic asthma from two centers, treating them with add-on biological therapy. The asthma control test (ACT) and the Short-form Health Survey-12 (SF-12), including Physical Component Summary (PCS) and Mental Component Summary (MCS), were used, assessing drug history at baseline (T0) and after 32 weeks of biological therapy (T1).
Results: A significant improvement in asthma control was observed after the biological treatment (ACT score: 11(8) vs 23(3), p < 0.0001), with most patients achieving asthma control at T1 (110, 86.6%). There was a statistically significant reduction in the use of non-biological drugs at T1, such as oral corticosteroids (40.2% vs 17.3%, p < 0.0001), inhalation therapy (75.6% vs 57.5%, p = 0.001), leukotriene receptor antagonists (34.6% vs 25.2%, p < 0.0001), and antihistamines (42.5% vs 18.1%, p < 0.0001). ACT and PCS scores at T1 had a strong positive correlation (r = 0.749, p < 0.0001), as did ACT and MCS scores (r = 0.744, p < 0.0001). Our study shows that the biological treatments for severe eosinophilic asthma, properly characterized through a careful phenotypic assessment, significantly improve asthma control and reduce drug burden (notably oral corticosteroids, inhalation therapy, leukotriene receptor antagonists, and antihistamines), as well as enhance both physical and mental health irrespective of age and sex.
期刊介绍:
Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.